The use of pharmacotherapy in the prodrome of schizophrenia

CNS Spectrums

Volumn 9, Issue 8, 2004, Pages 579-586

  Remington, Gary ^a,b   Shammi, Chekkera ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT;

EID: 4444312902     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900002741     Document Type: Review

References (60)

1. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry. 1982;39:70-73.
2. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995;52:173-188.
3. Amminger GP, Edwards J, Brewer WJ, Harrigan S, McGorry PD. Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophr Res. 2002;54:223-230.
4. Bottlender R, Strauss A, Moller HJ. Impact of duration of symptoms prior to first hospitalisation on acute outcome in 998 schizophrenic patients. Schizophr Res. 2000;44:145-150.
5. Drake RJ, Haley CJ, Akhtar S, Lewis SW. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry. 2000;177:511-515.
6. Malla AK, Norman RM, Manchanda R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res. 2002;54:231-242.
7. Verdoux H, Liraud F, Bergey C, Assens F, Abalan F, van Os J. Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophr Res. 2001;49:231-241.
8. Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychol Med. 1997;27:261-268.
9. Lieberman JA. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J Clin Psychiatry. 1999;60(suppl 12):9-12.
10. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999;46:729-739.
11. Hafner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry. 1997;42:139-151.
12. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22:353-370.
13. Keshavan MS, Carter CS. First-episode schizophrenia: a phase-specific approach to management. Primary Psychiatry. 2000;7:43-50.
14. Lieberman JA, Perkins D, Beiger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50:884-897.
15. DeGrazia D. Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia. Schijophr Res. 2001;51:77-86.
16. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res. 2001;51:31-38.
17. McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res. 2001;51:47-54.
18. McGlashan TH, Miller TJ, Woods SW Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull. 2001;27:563-570.
19. McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res. 2001;51:17-29.
20. Fennig S, Kovasznay B, Rich C, et al. Six-month stability of psychiatric diagnoses in first-admission patients with psychosis. Am J Psychiatry. 1994;151:1200-1208.
21. Munk-Jorgensen P. The schizophrenia diagnosis in Denmark. A register-based investigation. Acta Psychiatr Scand. 1985;72:266-273.
22. Lenz G, Simhandl, C, Thau K. Temporal stability and predictive validity of diagnostic criteria for schizophrenia [abstract]. Schizophr Res. 1992;6:170.
23. Addington J. The prodromal stage of psychotic illness: observation, detection, or intervention? Psychiatry Neurosci. 2003;28:93-97.
24. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60:21-32.
25. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand. 2003;107:85-95.
26. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychone uroendocrinology. 2003;28(suppl 1):83-96.
27. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs. 2002;16:77-89.
28. Hoff AL, Sakuma M, Razi K, Heydebrand G, Csernansky JG, DeLisi LE. Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia. Am J Psychiatry. 2000;157:1824-1828.
29. Norman RM, Townsend L, Malla AK. Duration of untreated psychosis and cognitive functioning in first-episode patients. Br J Psychiatry. 2001;179:340-345.
30. Craig TJ, Bromet EJ, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry. 2000;157:60-66.
31. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry. 1999;156:1336-1341.
32. Robinson DG, Woerner M, McMeniman M. Recovery in first episode schizophrenia. Schizophr Res. 2003;60(suppl):301.
33. Woods SW, Breier A, Zipursky RB, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004:161:473-479.
34. Tsuang MT, Stone WS, Seidman LJ, et al. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biol Psychiatry. 1999;45:1412-1418.
35. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59:921-928.
36. Cornblatt B, Lencz T, Correll C, Author A, Smith C. Treating the prodrome: naturalistic findings from the RAP program. Acta Psychiatr Scand. 2002;106(suppl):44.
37. Cannon TD, Huttunen MO, Dahlstrom M, Larmo I, Rasanen P, Juriloo A. Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am J Psychiatry. 2002:159:1230-1232.
38. Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention. Can J Psychiatry. 2002;47:518-526.
39. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
40. Buckley PF. New antipsychotic agents: emerging clinical profiles. J Clin Psychiatry. 1999;60(suppl 1):12-17.
41. Waddington JL, O'Callaghan E. What makes an antipsychotic 'atypical'? CNS Drugs. 1997:7:341-346.
42. Remington G, Shammi CM, Sethna R, Lawrence R. Antipsychotic dosing patterns for schizophrenia in three treatment settings. Psychiatr Serv. 2001;52:96-98.
43. Remington G, Kapur S, Zipursky B. Pharmacotherapy of first episode psychosis. In: Miller T, Mednick SA, McGlashan TH, Libiger J, Johannessen JO, eds. Early Intervention in Psychotic Disorders. vol 91. London, England: Kluwer Academic Publishers; 2001:167-180.
44. Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Can J Psychiatry. 1997;42:53-57.
45. Kapur S, Zipursky RB, Jones C, Remington GJ, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520.
46. Zhang-Wong J, Zipursky RB, Beiser M, Bean G. Optimal haloperidol dosage in first-episode psychosis. Can J Psychiatry. 1999;44:164-167.
47. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(suppl 9):5-9.
48. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, Hernandez J, Gomez-Beneyto M, Schooler NR. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry. 1994;151:1819-1821.
49. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry. 2002;51:972-978.
50. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51-68.
51. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in aBMJ. 2000;321:1371-1376.
52. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry. 1999;174:23-30.
53. Emsley R, the Risperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull. 1999;25:721-729.
54. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical anti-psychotics. A retro- and prospective study of extrapyramidal side effects. Psychophormacology. 1996;124:188-196.
55. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 2000;61(suppl 4):21-26.
56. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997;154:1248-1254.
57. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriotr Soc. 1999;47:716-719.
58. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157:1150-1155.
59. Morrison AP, Bentall RP, French P, et al. Randomised controlled trial of early detection and cognitive therapy fpr preventing transition to psychosis: study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry. 2002;181(suppl 3):S78-S84.
60. Sackett DL. The arrogance of preventive medicine. CMAJ. 2002;167:363-364.